MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-03-2026
Intuitive Surgical Balance Sheet 2011-2026 | ISRG
Annual Balance Sheet Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.2 B | -1.88 B | -2.68 B | -1.51 B | -1.22 B | - | -1.17 B | -858 M | -648 M | -1.04 B | -715 M | -600 M | -782 M | -554 M | -466 M |
Long Term Debt |
132 M | 112 M | 64.5 M | 69.6 M | 66.6 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
39 M | 33.5 M | 25.3 M | 24.2 M | 20.4 M | 21.9 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 418 M | 339 M | 327 M | 113 M | 95.9 M | 78.8 M | 68 M | 77.5 M | 96.9 M |
Total Current Liabilities |
2.01 B | 1.75 B | 1.66 B | 1.42 B | 1.15 B | 965 M | 1.03 B | 821 M | 704 M | 596 M | 492 M | 501 M | 381 M | 402 M | 321 M |
Total Liabilities |
2.52 B | 2.21 B | 2.04 B | 1.86 B | 1.6 B | 1.41 B | 1.45 B | 1.16 B | 1.03 B | 709 M | 588 M | 580 M | 449 M | 479 M | 418 M |
Deferred Revenue |
507 M | 469 M | 446 M | 397 M | 377 M | 350 M | 338 M | 294 M | 284 M | 241 M | 226 M | 217 M | 200 M | 186 M | 154 M |
Retained Earnings |
7.01 B | 6.8 B | 4.74 B | 3.5 B | 4.76 B | 3.26 B | 2.49 B | 1.52 B | 61.4 M | 1.57 B | 899 M | 488 M | 979 M | 1.33 B | 902 M |
Total Assets |
20.5 B | 18.7 B | 15.4 B | 13 B | 13.6 B | 11.2 B | 9.73 B | 7.85 B | 5.76 B | 6.49 B | 4.91 B | 3.96 B | 3.95 B | 4.06 B | 3.06 B |
Cash and Cash Equivalents |
3.37 B | 2.03 B | 2.77 B | 1.6 B | 1.31 B | 1.64 B | 1.17 B | 858 M | 648 M | 1.04 B | 715 M | 600 M | 782 M | 554 M | 466 M |
Book Value |
17.9 B | 16.5 B | 13.4 B | 11.1 B | 12 B | 9.76 B | 8.28 B | 6.69 B | 4.73 B | 5.78 B | 4.32 B | 3.38 B | 3.5 B | 3.58 B | 2.65 B |
Total Shareholders Equity |
17.8 B | 16.4 B | 13.4 B | 11.1 B | 12 B | 9.76 B | 8.26 B | 6.68 B | 4.73 B | 5.78 B | 4.32 B | 3.38 B | 3.5 B | 3.58 B | 2.65 B |
All numbers in USD currency
Quarterly Balance Sheet Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 66.6 M | - | - | - | 58 M | - | - | - | 68.7 M | 72.2 M | 69.6 M | 71.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.31 B | 2.21 B | 2.01 B | 2.21 B | 2.07 B | 1.85 B | 1.78 B | 2.04 B | 2.09 B | - | 1.76 B | 1.86 B | 1.69 B | - | 1.52 B | 1.6 B | 1.48 B | 1.42 B | 1.35 B | 1.41 B | 1.41 B | 1.41 B | 1.41 B | 1.45 B | 1.45 B | 1.45 B | 1.45 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 996 M | 996 M | 996 M | 996 M | 709 M | 709 M | 709 M | 709 M | 588 M | 588 M | 588 M | 588 M | 580 M | 580 M | 580 M | 580 M | 449 M | 449 M | 449 M | 449 M | 479 M | 479 M | 479 M | 479 M | 418 M | 418 M | 418 M | 418 M |
Deferred Revenue |
491 M | 500 M | 496 M | 469 M | 426 M | 434 M | 438 M | 446 M | 395 M | - | 418 M | 397 M | 359 M | - | 386 M | 377 M | 348 M | 360 M | 358 M | 350 M | 350 M | 350 M | 350 M | 338 M | 338 M | 338 M | 338 M | 294 M | 294 M | 294 M | 294 M | 244 M | 244 M | 244 M | 244 M | 241 M | 241 M | 241 M | 241 M | 226 M | 226 M | 226 M | 226 M | 217 M | 217 M | 217 M | 217 M | 200 M | 200 M | 200 M | 200 M | 186 M | 186 M | 186 M | 186 M | 154 M | 154 M | 154 M | 154 M |
Retained Earnings |
6.42 B | 7.61 B | 7.14 B | 6.8 B | 6.13 B | 5.58 B | 5.07 B | 4.74 B | 4.21 B | - | 3.4 B | 3.5 B | 4.02 B | - | 4.86 B | 4.76 B | 4.39 B | 4.02 B | 3.51 B | 3.26 B | 3.26 B | 3.26 B | 3.26 B | 2.49 B | 2.49 B | 2.49 B | 2.49 B | 1.52 B | 1.52 B | 1.52 B | 1.52 B | 115 M | 115 M | 115 M | 115 M | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 899 M | 899 M | 899 M | 899 M | 488 M | 488 M | 488 M | 488 M | 979 M | 979 M | 979 M | 979 M | 1.33 B | 1.33 B | 1.33 B | 1.33 B | 902 M | 902 M | 902 M | 902 M |
Total Assets |
19.4 B | 20.2 B | 19.2 B | 18.7 B | 17.7 B | 16.6 B | 15.8 B | 15.4 B | 14.7 B | - | 13.1 B | 13 B | 13.3 B | - | 13.7 B | 13.6 B | 12.9 B | 12.3 B | 11.5 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 9.73 B | 9.73 B | 9.73 B | 9.73 B | 7.85 B | 7.85 B | 7.85 B | 7.85 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 6.49 B | 6.49 B | 6.49 B | 6.49 B | 4.91 B | 4.91 B | 4.91 B | 4.91 B | 3.96 B | 3.96 B | 3.96 B | 3.96 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 4.06 B | 4.06 B | 4.06 B | 4.06 B | 3.06 B | 3.06 B | 3.06 B | 3.06 B |
Cash and Cash Equivalents |
2.81 B | 3.4 B | 2.57 B | 2.03 B | 2.45 B | 3.07 B | 2.87 B | 2.75 B | 3.62 B | 3.46 B | 2.17 B | 1.58 B | 1.55 B | - | 1.12 B | 1.29 B | 1.36 B | 1.62 B | 1.4 B | 1.62 B | 1.62 B | 1.62 B | 1.62 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 858 M | 858 M | 858 M | 858 M | 648 M | 648 M | 648 M | 648 M | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 715 M | 715 M | 715 M | 715 M | 600 M | 600 M | 600 M | 600 M | 782 M | 782 M | 782 M | 782 M | 554 M | 554 M | 554 M | 554 M | 466 M | 466 M | 466 M | 466 M |
Book Value |
17 B | 18 B | 17.2 B | 16.5 B | 15.7 B | 14.8 B | 14 B | 13.4 B | 12.6 B | - | 11.3 B | 11.1 B | 11.6 B | - | 12.2 B | 12 B | 11.5 B | 10.9 B | 10.2 B | 9.76 B | 9.76 B | 9.76 B | 9.76 B | 8.28 B | 8.28 B | 8.28 B | 8.28 B | 6.69 B | 6.69 B | 6.69 B | 6.69 B | 4.78 B | 4.78 B | 4.78 B | 4.78 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 4.32 B | 4.32 B | 4.32 B | 4.32 B | 3.38 B | 3.38 B | 3.38 B | 3.38 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 3.58 B | 3.58 B | 3.58 B | 3.58 B | 2.65 B | 2.65 B | 2.65 B | 2.65 B |
Total Shareholders Equity |
16.9 B | 17.8 B | 17.1 B | 16.4 B | 15.7 B | 14.8 B | 14 B | 13.3 B | 12.6 B | 12 B | 11.3 B | 11 B | 11.6 B | - | 12.2 B | 11.9 B | 11.5 B | 10.8 B | 10.2 B | 9.73 B | 9.73 B | 9.73 B | 9.73 B | 8.26 B | 8.26 B | 8.26 B | 8.26 B | 6.68 B | 6.68 B | 6.68 B | 6.68 B | 4.78 B | 4.78 B | 4.78 B | 4.78 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 4.32 B | 4.32 B | 4.32 B | 4.32 B | 3.38 B | 3.38 B | 3.38 B | 3.38 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 3.58 B | 3.58 B | 3.58 B | 3.58 B | 2.65 B | 2.65 B | 2.65 B | 2.65 B |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Intuitive Surgical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Merit Medical Systems
MMSI
|
$ 67.55 | -0.85 % | $ 4 B |  USA |
 |
ICU Medical
ICUI
|
$ 129.4 | -0.41 % | $ 3.19 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.03 | 0.81 % | $ 4.37 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.5 | -0.94 % | $ 25.5 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Pro-Dex
PDEX
|
$ 49.99 | 4.25 % | $ 164 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.29 | 1.72 % | $ 1.43 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Nephros
NEPH
|
$ 3.05 | -1.93 % | $ 31.7 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 56.66 | -3.08 % | $ 2.85 B | USA |
 |
Baxter International
BAX
|
$ 16.72 | 0.57 % | $ 8.58 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.06 | -0.65 % | $ 225 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.63 | -0.75 % | $ 434 M | USA |
 |
Repligen Corporation
RGEN
|
$ 116.3 | -0.04 % | $ 6.48 M | USA |
 |
AtriCure
ATRC
|
$ 29.61 | -0.57 % | $ 1.41 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.69 | 0.94 % | $ 200 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 118.69 | 0.47 % | $ 3.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.7 | 2.76 % | $ 908 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 3.78 % | $ 23.1 M | USA |
 |
electroCore
ECOR
|
$ 6.17 | 0.65 % | $ 52.3 K | USA |
 |
STERIS plc
STE
|
$ 221.73 | 0.33 % | $ 21.9 B | USA |
 |
Stereotaxis
STXS
|
$ 1.8 | -2.17 % | $ 164 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 106.56 | 0.67 % | $ 4.75 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 105.23 | -1.51 % | $ 5.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 63.8 | -2.04 % | $ 232 M | USA |
 |
ResMed
RMD
|
$ 228.19 | 0.1 % | $ 33.3 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.5 | -0.79 % | $ 25.5 M |  Israel |
 |
West Pharmaceutical Services
WST
|
$ 245.27 | 1.6 % | $ 17.7 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.72 | -0.04 % | $ 21.6 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.47 | -0.65 % | $ 2.29 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
The Cooper Companies
COO
|
$ 70.49 | 0.36 % | $ 14 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.97 | 2.49 % | $ 940 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 5.13 | -3.93 % | $ 228 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 155.92 | -0.19 % | $ 44.9 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.4 | -0.68 % | $ 203 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 109.99 | 1.97 % | $ 2.49 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.69 | 0.14 % | $ 9.52 B | USA |
 |
Alcon
ALC
|
$ 74.24 | 0.13 % | $ 40.4 B |  Schweiz |